Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling

Qing-Shuo Zhang, Eric Benedetti, Matthew Deater, Kathryn Schubert, Angela Major, Carl Pelz, Soren Impey, Laura Marquez-Loza, R. Keaney Rathbun, Shigeaki Kato, Grover C. Bagby, Markus Grompe

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Androgens are widely used for treating Fanconi anemia (FA) and other human bone marrow failure syndromes, but their mode of action remains incompletely understood. Aged Fancd2-/- mice were used to assess the therapeutic efficacy of oxymetholone (OXM) and its mechanism of action. Eighteen-month-old Fancd2-/- mice recapitulated key human FA phenotypes, including reduced bone marrow cellularity, red cell macrocytosis, and peripheral pancytopenia. As in humans, chronic OXM treatment significantly improved these hematological parameters and stimulated the proliferation of hematopoietic stem and progenitor cells. RNA-Seq analysis implicated downregulation of osteopontin as an important potential mechanism for the drug's action. Consistent with the increased stem cell proliferation, competitive repopulation assays demonstrated that chronic OXM therapy eventually resulted in stem cell exhaustion. These results expand our knowledge of the regulation of hematopoietic stem cell proliferation and have direct clinical implications for the treatment of bone marrow failure.

Original languageEnglish (US)
Pages (from-to)90-102
Number of pages13
JournalStem Cell Reports
Volume4
Issue number1
DOIs
StatePublished - Jan 13 2015

Fingerprint

Oxymetholone
Fanconi Anemia
Osteopontin
Transcription
Hematopoietic Stem Cells
Stem cells
Bone
Cell proliferation
Stem Cells
Bone Marrow
Cell Proliferation
Pancytopenia
Androgens
Assays
Therapeutics
Down-Regulation
Cells
RNA
Phenotype
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Developmental Biology
  • Genetics

Cite this

Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. / Zhang, Qing-Shuo; Benedetti, Eric; Deater, Matthew; Schubert, Kathryn; Major, Angela; Pelz, Carl; Impey, Soren; Marquez-Loza, Laura; Rathbun, R. Keaney; Kato, Shigeaki; Bagby, Grover C.; Grompe, Markus.

In: Stem Cell Reports, Vol. 4, No. 1, 13.01.2015, p. 90-102.

Research output: Contribution to journalArticle

Zhang, Q-S, Benedetti, E, Deater, M, Schubert, K, Major, A, Pelz, C, Impey, S, Marquez-Loza, L, Rathbun, RK, Kato, S, Bagby, GC & Grompe, M 2015, 'Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling', Stem Cell Reports, vol. 4, no. 1, pp. 90-102. https://doi.org/10.1016/j.stemcr.2014.10.014
Zhang, Qing-Shuo ; Benedetti, Eric ; Deater, Matthew ; Schubert, Kathryn ; Major, Angela ; Pelz, Carl ; Impey, Soren ; Marquez-Loza, Laura ; Rathbun, R. Keaney ; Kato, Shigeaki ; Bagby, Grover C. ; Grompe, Markus. / Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. In: Stem Cell Reports. 2015 ; Vol. 4, No. 1. pp. 90-102.
@article{c9711b2386704a95b535d7a37e6d4b52,
title = "Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling",
abstract = "Androgens are widely used for treating Fanconi anemia (FA) and other human bone marrow failure syndromes, but their mode of action remains incompletely understood. Aged Fancd2-/- mice were used to assess the therapeutic efficacy of oxymetholone (OXM) and its mechanism of action. Eighteen-month-old Fancd2-/- mice recapitulated key human FA phenotypes, including reduced bone marrow cellularity, red cell macrocytosis, and peripheral pancytopenia. As in humans, chronic OXM treatment significantly improved these hematological parameters and stimulated the proliferation of hematopoietic stem and progenitor cells. RNA-Seq analysis implicated downregulation of osteopontin as an important potential mechanism for the drug's action. Consistent with the increased stem cell proliferation, competitive repopulation assays demonstrated that chronic OXM therapy eventually resulted in stem cell exhaustion. These results expand our knowledge of the regulation of hematopoietic stem cell proliferation and have direct clinical implications for the treatment of bone marrow failure.",
author = "Qing-Shuo Zhang and Eric Benedetti and Matthew Deater and Kathryn Schubert and Angela Major and Carl Pelz and Soren Impey and Laura Marquez-Loza and Rathbun, {R. Keaney} and Shigeaki Kato and Bagby, {Grover C.} and Markus Grompe",
year = "2015",
month = "1",
day = "13",
doi = "10.1016/j.stemcr.2014.10.014",
language = "English (US)",
volume = "4",
pages = "90--102",
journal = "Stem Cell Reports",
issn = "2213-6711",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling

AU - Zhang, Qing-Shuo

AU - Benedetti, Eric

AU - Deater, Matthew

AU - Schubert, Kathryn

AU - Major, Angela

AU - Pelz, Carl

AU - Impey, Soren

AU - Marquez-Loza, Laura

AU - Rathbun, R. Keaney

AU - Kato, Shigeaki

AU - Bagby, Grover C.

AU - Grompe, Markus

PY - 2015/1/13

Y1 - 2015/1/13

N2 - Androgens are widely used for treating Fanconi anemia (FA) and other human bone marrow failure syndromes, but their mode of action remains incompletely understood. Aged Fancd2-/- mice were used to assess the therapeutic efficacy of oxymetholone (OXM) and its mechanism of action. Eighteen-month-old Fancd2-/- mice recapitulated key human FA phenotypes, including reduced bone marrow cellularity, red cell macrocytosis, and peripheral pancytopenia. As in humans, chronic OXM treatment significantly improved these hematological parameters and stimulated the proliferation of hematopoietic stem and progenitor cells. RNA-Seq analysis implicated downregulation of osteopontin as an important potential mechanism for the drug's action. Consistent with the increased stem cell proliferation, competitive repopulation assays demonstrated that chronic OXM therapy eventually resulted in stem cell exhaustion. These results expand our knowledge of the regulation of hematopoietic stem cell proliferation and have direct clinical implications for the treatment of bone marrow failure.

AB - Androgens are widely used for treating Fanconi anemia (FA) and other human bone marrow failure syndromes, but their mode of action remains incompletely understood. Aged Fancd2-/- mice were used to assess the therapeutic efficacy of oxymetholone (OXM) and its mechanism of action. Eighteen-month-old Fancd2-/- mice recapitulated key human FA phenotypes, including reduced bone marrow cellularity, red cell macrocytosis, and peripheral pancytopenia. As in humans, chronic OXM treatment significantly improved these hematological parameters and stimulated the proliferation of hematopoietic stem and progenitor cells. RNA-Seq analysis implicated downregulation of osteopontin as an important potential mechanism for the drug's action. Consistent with the increased stem cell proliferation, competitive repopulation assays demonstrated that chronic OXM therapy eventually resulted in stem cell exhaustion. These results expand our knowledge of the regulation of hematopoietic stem cell proliferation and have direct clinical implications for the treatment of bone marrow failure.

UR - http://www.scopus.com/inward/record.url?scp=84920849913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920849913&partnerID=8YFLogxK

U2 - 10.1016/j.stemcr.2014.10.014

DO - 10.1016/j.stemcr.2014.10.014

M3 - Article

C2 - 25434823

AN - SCOPUS:84920849913

VL - 4

SP - 90

EP - 102

JO - Stem Cell Reports

JF - Stem Cell Reports

SN - 2213-6711

IS - 1

ER -